康柏西普治疗视网膜静脉阻塞继发黄斑水肿临床观察  

A prospective randomized clinical trial on intravitreous injection of Conbercept for macular edema secondary to retinal vein occlusion

作　　者：周颖[1] 周明[1] 刘豪杰[1] 丁海祥[1] 

机构地区：[1]大连大学附属中山医院眼科,大连市116001

出　　处：《中国实用眼科杂志》2016年第6期597-600,共4页Chinese Journal of Practical Ophthalmology

摘　　要：目的观察玻璃体腔注射康柏西普治疗视网膜静脉阻塞（RVO）继发黄斑水肿的临床疗效及安全性。方法前瞻性、无对照、开放性研究。选取2014年3月至2015年4月在大连大学附属中山医院眼科临床确诊的RVO继发黄斑水肿的患者36例36只眼，行玻璃体腔内注射康柏西普（0．5mg，0．05ml）治疗。初始3月每月注射一次，随后按需进行重复注射。患者每月随诊一次，通过常规眼科检查、眼底照相、眼底荧光素血管造影（FFA）、光学相干断层扫描（OCT）等，观察最佳矫正视力（BCVA）、中央视网膜厚度（CRT）的变化以及出现的眼部相关不良反应，并与治疗前进行比较。结果BCVA，治疗后1、2、3、6月及末次随访，与治疗前相比，治疗后各个时间点的BCVA均有提高，且差异具有统计学意义（t=14．52、14．73、15．54、13．95、14．13，P〈0．05）。末次随访时视力提高有效32只眼（88．89％），稳定4只眼（11．11％），无无效眼。CRT，治疗后1、2、3、6月及末次随访，与治疗前相比，治疗后各个时间点的CRT平均值均有所下降，且差异具有统计学意义（t=8．36、8．45、6．99、7．09、11．97，P〈0．05）。末次随访时显示36只眼（100％）黄斑水肿均有所吸收，18只眼（50％）黄斑水肿消退。并发症方面，所有患者随访期间均未出现玻璃体出血、视网膜脱离、持续高眼压和眼内炎等并发症。结论短期内玻璃体腔注射康柏西普治疗RVO继发黄斑水肿安全有效，可以改善视力，减轻黄斑水肿。Objective To evaluate the effects and safety of intravitreous injection of Conbercept for macular edema secondary to retinal vein occlusion. Methods Clinical records of 36 patients （36 eyes） with macular edema secondary to RVO who were treated with an intraviteral dose of 0.5mg or 0.05ml Conbercept Ophthalmic Injection. All patients were evaluated by complete ophthalmic examination, fundus fluorescein angiography （FFA） and optical coherence tomography （OCT）, ect, Best corrected visual acuity （BCVA）, central retinal thickness （CRT） were observed at 1, 2, 3, 6 months and the latest follow up after treatment with compared with before treatment. Results During the 1, 2, 3, 6 months after treatment and the latest follow up, the mean BCVA were all improved with statistically significant difference （t =14.52, 14.73, 15.54, 13.95, 14.13, P 〈0.05）. At latest follow up, the mean BCVA was obviously improved in 32 eyes （88.89%）, stable in 4 eyes （11.11%）, invalid in 0 eye （0%）. During the 1, 2, 3, 6 months after treatment and the latest follow up, the mean CRT were all improved with statistically significant difference （t =8.36, 8.45, 6.99, 7.09, 11.97, P 〈0.05）. At latest follow up, the leakage in macular lutea decreased in 36 eyes （100%）, disappeared in 18 eyes （50%）. No adverse events such as secondary retinal detachment or endoophthalmitis were found during the follow-up duration. Conclusions Intravitreous injection of Conbercept for macular edema secondary to RVO can improve visual acuity, relieve macular edema, which is effective and safe in the short term.

关 键 词：视网膜静脉阻塞 黄斑水肿 康柏西普 眼内注射 

分 类 号：R774.1[医药卫生—眼科]